Abstract

A REVIEW ON: NOVEL DRUG DELIVERY TECHNOLOGY OF RITUXIMAB

Ni Made Dwi Indrayuni*, Erfan Tri E., Baharudin Irfan, Sari Kusuma Hati and Siti Saharah Abdullah

Abstract

Rituximab can be used for the treatment of severe rheumatoid arthritis, follicular lymphoma phase III-IV, follicular non-hodgkins lymphoma, chronic lymphocytic leukimia therapy, advance therapy of granulomatosis polyangiitis and microscopic polyitis. Rituximab is a two compartment with an average half-life of 87 ± 18 hours and a volume distribution of 1.3L. Administration of rituximab at a dose of 375 mg / m2 in 4 consecutive weeks can increase serum drug concentration in each administration by infusion. This review article focuses on biosimilar technology of rituximab was carried out by increasing the teraupetic mechanism and the response to the potential effects of binding B-mAB in NHL disease. The development of biosimilar rituximab approved by the FDA, namely ofatumab (anti CD20) and Obinutuzumab (mAb from rituximab with a different glucose group).

Keywords: Rituximab, Biosimilar, NHL disease.